Luminex partners with Abbott for newly cleared xTAG RVP test
This article was originally published in Clinica
Executive Summary
Biological testing specialist Luminex has struck a deal with Abbott's molecular diagnostic business for the worldwide distribution of the former's xTAG respiratory viral panel (RVP). The deal, of which financial details were not revealed, will see Abbott gain semi-exclusive distribution rights to the product in the US, and exclusive rights for non-US markets. The xTAG RVP is based on Luminex's xMAP multiplexing technology and, according to the Austin, Texas-based company, can simultaneously test for twelve viruses and viral subtypes within a few hours after a patient sample is taken. The xTAG received 510(k) clearance from the US FDA in January 2008 (see Clinica No 1289, p 18).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.